Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the
Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the radiopharmaceuticalsdivision of Du Pont Merck Pharmaceutical. He also held positionsat American Hospital Supply, where he developed an understandingof the injectable drug market, which will be key to marketingSonus' agents, according to the company.
Sonus, of Costa Mesa, CA, is developing intravenous ultrasoundcontrast agents based on a dodecafluoropentane-based emulsion.The company has filed an investigational new drug (IND) applicationwith the Food and Drug Administration for EchoGen, a cardiac contrastagent (SCAN 1/19/94).
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.